FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 292 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Sacituzumab Govitecan Improves Outcomes Over Single-Agent Chemotherapy in Patients with Pretreated... March 5, 2024 Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian... March 1, 2019 Study Adds to Debate about Screening for Melanoma May 4, 2022 Why it’s difficult to estimate the number of extra cancer deaths... July 21, 2020 Load more HOT NEWS Repurposing radiotherapy drugs could give immunotherapy a boost Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive... A new approach to cancer immunotherapy FDA Approves New Dosing Regimen for Cetuximab
